Bright Minds Biosciences Inc.
CNSXDRUG heads into its August 20 earnings print with a notable shift from the picture painted just two days ago: short interest has quietly rebuilt after its collapse, rising more than 700% in a single session on August 18 to reach roughly 4,150 shares — though that still amounts to less than 0.06% of the free float. The short positioning reversal is real but needs context. Two days…
DRUG short interest
Full pulse commentary is for ORTEX subscribers. The live data picture for DRUG below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →DRUG heads into its August 20 earnings print with a notable shift from the picture painted just two days ago: short interest has quietly rebuilt after its collapse, rising more than 700% in a single session on August…
DRUG enters its August 20 earnings event with one of the more striking positioning shifts in recent weeks: short sellers have cut their exposure by more than 70% over the past month. Short interest has collapsed from…
Short interest % of float, cost to borrow, utilization, and put/call ratio for DRUG are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 20 Aug 2026
Bright Minds Biosciences heads into its earnings release with a striking split: the loudest voice on the Street just turned more bullish, while short sellers have been piling in at a pace not seen in months. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DRUG — free to start on ORTEX.
Sign up for free →Open DRUG on ORTEX